Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 263

1.

[Practical guide for the use of biological agents in rheumatoid arthritis - December 2011 update].

Mourão AF, Fonseca JE, Canhão H, Santos MJ, Bernardo A, Cordeiro A, Cravo AR, Ribeiro A, Teixeira A, Barcelos A, Malcata A, Faustino A, Duarte C, Ribeiro C, Nour D, Araújo D, Sousa E, Mariz E, Ramos F, Vinagre F, Ventura FS, Sequeira G, Santos H, Branco JC, Gomes JA, Silva JA, Ramos J, Santo JE, Costa JA, Silva JA, Ribeiro JS, Inês L, Miranda L, Sampaio L, Costa ML, Rodrigues M, Afonso MC, Cunha MI, Saavedra MJ, Queiroz MV, Couto M, Bernardes M, Bogas M, Pinto P, Valente P, Coelho P, Abreu P, Cortes S, Pimenta S, Ramiro S, Figueira R, Nóvoa T; Grupo de Estudo de Artrite Reumatóide da Sociedade Portuguesa de Reumatologia.

Acta Reumatol Port. 2011 Oct-Dec;36(4):389-95. Portuguese.

PMID:
22472930
[PubMed - indexed for MEDLINE]
Free Article
2.

Markers of progression to rheumatoid arthritis: discriminative value of the new ACR/EULAR rheumatoid arthritis criteria in a Portuguese population with early polyarthritis.

Mourão AF, Canhão H, Moura RA, Cascão R, Weinmann P, Rodrigues A, Polido-Pereira J, Resende C, Capela S, Silva JA, Fonseca JE.

Acta Reumatol Port. 2011 Oct-Dec;36(4):370-6.

PMID:
22472927
[PubMed - indexed for MEDLINE]
Free Article
3.

Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients.

Owen SA, Hider SL, Martin P, Bruce IN, Barton A, Thomson W.

Pharmacogenomics J. 2013 Jun;13(3):227-34. doi: 10.1038/tpj.2012.7. Epub 2012 Mar 27.

PMID:
22450926
[PubMed - indexed for MEDLINE]
4.

Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.

Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, Geurts MA, van der Werf JH, van Albada-Kuipers GA, Jahangier-de Veen ZN, van der Veen MJ, Verhoef CM, Lafeber FP, Bijlsma JW; Utrecht Rheumatoid Arthritis Cohort Study Group.

Ann Intern Med. 2012 Mar 6;156(5):329-39. doi: 10.7326/0003-4819-156-5-201203060-00004.

PMID:
22393128
[PubMed - indexed for MEDLINE]
5.

Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis.

Ercan A, Cui J, Hazen MM, Batliwalla F, Royle L, Rudd PM, Coblyn JS, Shadick N, Weinblatt ME, Gregersen P, Lee DM, Nigrovic PA.

Arthritis Res Ther. 2012 Mar 5;14(2):R43. doi: 10.1186/ar3756.

PMID:
22390545
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

The challenges of methotrexate pharmacogenetics in rheumatoid arthritis.

Ranganathan P.

Pharmacogenomics. 2012 Mar;13(4):377. doi: 10.2217/pgs.12.13. No abstract available.

PMID:
22379994
[PubMed - indexed for MEDLINE]
7.

Diagnostic value of antibodies to modified citrullinated vimentin in early rheumatoid arthritis.

Sizova L.

Hum Immunol. 2012 Apr;73(4):389-92. doi: 10.1016/j.humimm.2012.01.007. Epub 2012 Feb 2.

PMID:
22333689
[PubMed - indexed for MEDLINE]
8.

Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis.

Milic V, Jekic B, Lukovic L, Bunjevacki V, Milasin J, Novakovic I, Damnjanovic T, Popovic B, Maksimovic N, Damjanov N, Radunovic G, Pejnovic N, Krajinovic M.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2):178-83. Epub 2012 Apr 13.

PMID:
22324981
[PubMed - indexed for MEDLINE]
9.

Role of anti-citrullinated protein antibodies in diagnosis and prognosis of rheumatoid arthritis.

Puszczewicz M, Iwaszkiewicz C.

Arch Med Sci. 2011 Apr;7(2):189-94. doi: 10.5114/aoms.2011.22067. Epub 2011 May 17.

PMID:
22291756
[PubMed]
Free PMC Article
10.

Remission in early rheumatoid arthritis: predicting treatment response.

Ma MH, Ibrahim F, Walker D, Hassell A, Choy EH, Kiely PD, Williams R, Walsh DA, Young A, Scott DL.

J Rheumatol. 2012 Mar;39(3):470-5. doi: 10.3899/jrheum.110169. Epub 2012 Jan 15.

PMID:
22247360
[PubMed - indexed for MEDLINE]
11.

The presence of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor on patients with rheumatoid arthritis (RA) does not interfere with the chance of clinical remission in a follow-up of 3 years.

da Mota LM, Dos Santos Neto LL, de Carvalho JF, Pereira IA, Burlingame R, Ménard HA, Laurindo IM.

Rheumatol Int. 2012 Dec;32(12):3807-12. doi: 10.1007/s00296-011-2260-9. Epub 2011 Dec 21.

PMID:
22187055
[PubMed - indexed for MEDLINE]
12.

A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate.

Hobl EL, Jilma B, Erlacher L, Duhm B, Mustak M, Bröll H, Högger P, Rizovski B, Mader RM.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2):156-63. Epub 2012 Apr 13.

PMID:
22152098
[PubMed - indexed for MEDLINE]
13.

The pathogenesis of rheumatoid arthritis.

McInnes IB, Schett G.

N Engl J Med. 2011 Dec 8;365(23):2205-19. doi: 10.1056/NEJMra1004965. Review. No abstract available.

PMID:
22150039
[PubMed - indexed for MEDLINE]
14.

Response to traditional disease-modifying anti-rheumatic drugs in indigent South Africans with early rheumatoid arthritis.

Hodkinson B, Musenge E, Ally M, Meyer PW, Anderson R, Tikly M.

Clin Rheumatol. 2012 Apr;31(4):613-9. doi: 10.1007/s10067-011-1900-5. Epub 2011 Dec 2.

PMID:
22134750
[PubMed - indexed for MEDLINE]
15.

The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study.

van den Broek M, Dirven L, Klarenbeek NB, Molenaar TH, Han KH, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF.

Ann Rheum Dis. 2012 Feb;71(2):245-8. doi: 10.1136/annrheumdis-2011-200379. Epub 2011 Nov 21.

PMID:
22110122
[PubMed - indexed for MEDLINE]
16.

Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis.

Kato T, Hamada A, Mori S, Saito H.

Drug Metab Pharmacokinet. 2012;27(2):192-9. Epub 2011 Nov 22.

PMID:
22104130
[PubMed - indexed for MEDLINE]
Free Article
17.

Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis.

Dervieux T, Wessels JA, Kremer JM, Padyukov L, Seddighzadeh M, Saevarsdottir S, van Vollenhoven RF, Klareskog L, Huizinga TW, Guchelaar HJ.

Pharmacogenet Genomics. 2012 Jan;22(1):1-9. doi: 10.1097/FPC.0b013e32834d3e0b.

PMID:
22044941
[PubMed - indexed for MEDLINE]
18.

Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases.

Stamp LK, Roberts RL.

Pharmacogenomics. 2011 Oct;12(10):1449-63. doi: 10.2217/pgs.11.86. Review.

PMID:
22008049
[PubMed - indexed for MEDLINE]
19.

MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms.

Owen SA, Lunt M, Bowes J, Hider SL, Bruce IN, Thomson W, Barton A.

Pharmacogenomics J. 2013 Apr;13(2):137-47. doi: 10.1038/tpj.2011.42. Epub 2011 Sep 20.

PMID:
21931346
[PubMed - indexed for MEDLINE]
20.

Rheumatoid arthritis: what is refractory disease and how to manage it?

Polido-Pereira J, Vieira-Sousa E, Fonseca JE.

Autoimmun Rev. 2011 Sep;10(11):707-13. doi: 10.1016/j.autrev.2011.04.023. Epub 2011 May 5. Review.

PMID:
21570496
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk